Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Adam Esbenshade

9 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCPED1258

09/06/2012

Mutations in DICER1 and Related MicroRNA Processing Genes in Dysplasias, Dysontogenic Diseases, Tumors and Other Conditions

Other

COGACNS02B3

02/04/2013

ACNS02B3 - A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens

Other

VICCPED1251

05/31/2012

Supplemental Empiric Antibiotics in Unstable Febrile Neutropenia: Indications and Outcomes - CHART REVIEW

Other

VICCPED1145

12/02/2011

Cefepime Use in Newly Diagnosed Pediatric Patients with Leukemia or Lymphoma (Retrospective Chart Review)

Supportive Care

COGACCL1131

06/12/2013

A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFi Following Allogeneic Hematopoietic Cell Transplantation (HCT)

Supportive Care

VICCPED1309

03/29/2013

ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients

Supportive Care

COGACCL0922

02/20/2013

SCUSF0901 - ACCL0922: A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

Treatment

COGACNS0821

10/08/2011

ACNS0821 - Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

Treatment

COGACNS0831

05/12/2011

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years.